Valneva: 10% increase in sales by 2024

(CercleFinance.com) - Valneva reports a 10% increase in sales to 169.
6 million euros for 2024, including sales growth of 13% to 163.3 million, thus meeting its targets, despite lower-than-expected sales of Ixchiq in the United States.

It also boasts a solid cash position of 168.3 million euros at the end of 2024, as well as progress 'enabling us to anticipate the announcement of various clinical results, product approvals and potential indication expansions in 2025'.

For 2025, the vaccines company anticipates sales of 170 to 180 million euros, sales of 180 to 190 million euros, and operating cash consumption of less than 30 million euros, compared with over 60 million euros last year.

Copyright (c) 2025 CercleFinance.com. All rights reserved.